SB505124 is identified as a reversible ATP competitive and selective ALK inhibitor of ALK4 and ALK5. SB505124 shows no toxicity to renal epithelial A498 cells at concentrations up to 100 ¦ÌM for 48 hours, and blocks TGF-¦Â¨Cinduced apoptosis of FaO cells and NRP 154 cells in a concentration-dependent manner. In human umbilical vein endothelial cells (HUVEC), SB505124 (500 nM) blocks the changes of TGF-¦Â1 on F-actin assembly and prevents ROS production induced by TGF-¦Â. By inhibiting TGF-beta1 signaling, SB505124 leads to decreased deferoxamine (DFO)-induced neurogenesis. A recent study shows that SB505124 suppresses the migration and invasion of breast cancer MCF-7-M5 cells.

June 21, 2017

prudect name : SB505124 is identified as a reversible ATP competitive and selective ALK inhibitor of ALK4 and ALK5. SB505124 shows no toxicity to renal epithelial A498 cells at concentrations up to 100 ¦ÌM for 48 hours, and blocks TGF-¦Â¨Cinduced apoptosis of FaO cells and NRP 154 cells in a concentration-dependent manner. In human umbilical vein endothelial cells (HUVEC), SB505124 (500 nM) blocks the changes of TGF-¦Â1 on F-actin assembly and prevents ROS production induced by TGF-¦Â. By inhibiting TGF-beta1 signaling, SB505124 leads to decreased deferoxamine (DFO)-induced neurogenesis. A recent study shows that SB505124 suppresses the migration and invasion of breast cancer MCF-7-M5 cells.
SB-505124

Synonyms: CAS NO: 694433-59-5Molecular Formula: C₂₀H₂₁N₃O₂Molecular Weight: 335.40Purity: 98% minSolubility: In DMSOStorage: -20°C

web site: www.medchemexpress.com